Document is current
Any future updates will be listed below
-
Authors
Li, Na
Liu, Xiaoqin
Wang, Qiong
Chen, Yushu
Han, Chao
Qu, Chao
Guan, Xin
Zou, Wei
Wang, Xiaomin
Li, Ang
Zhang, Yin
Zhu, Liping
Du, Ruoyutong
Liu, Jing
Wang, Yanfu https://orcid.org/0000-0002-2179-4001
-
Funding
Funding for this research was provided by:
Liaoning Province Key Science and Technology Project (No.2022JH1/10800070)
Dalian High-Level Talent Innovation Program (No.2021RQ028)
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 9 April 2025
First Online: 2 August 2025
Declarations
:
: This study was performed at the Stem Cell Clinical Research Center of the First Affiliated Hospital of Dalian Medical University. This study was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University (Project Title: Research on the Treatment of Sarcopenia Using Human Umbilical Cord Mesenchymal Stem Cells Combined with Phytomedicine; Approval No. YJ-GZR-SQ-2024–69; Approved on March 5, 2024). The ethical approval covered the collection of umbilical cord specimens, which were obtained from healthy fetuses delivered by cesarean section. Informed consent was provided by all pregnant women participants and their family members prior to specimen collection. All animal experiments were performed in strict accordance with the ethical guidelines established by the Animal Research Ethics Committee of Dalian Medical University (Project Title: Research on the Treatment of Sarcopenia with Human Umbilical Cord Mesenchymal Stem Cells Combined with Epimedium; Approval No. AEE24221; Approved on January 9, 2024).
: All authors reviewed and endorsed the final version of the manuscript for submission and publication.
: The authors declare that no AI-generated content was used in this manuscript.
: The authors declare that they have no competing interests.
